D-0247-2021 Class III Terminated

Recalled by Lupin Pharmaceuticals Inc. — Baltimore, MD

FDA drug recall D-0247-2021 was initiated by Lupin Pharmaceuticals Inc. on Jan 21, 2021 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications; Out-of-specification test results observed for Impurity C at 9 month long-term stability time point. The recall status is terminated (terminated Dec 16, 2021). Affected quantity: 46,479 bottles.

Recall details

Product Type
Drugs
Report Date
Feb 10, 2021
Initiation Date
Jan 21, 2021
Termination Date
Dec 16, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
46,479 bottles

Product description

Oseltamivir Phosphate for Oral Suspension, 6 mg/mL, 60 mL (usable volume after constitution), Rx only, Manufactured for:Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202, Manufactured by: Lupin Limited Aurangabad, Maharashtra, India. NDC: 68180-678-01

Reason for recall

Failed Impurities/Degradation Specifications; Out-of-specification test results observed for Impurity C at 9 month long-term stability time point.

Distribution pattern

Nationwide

Code information

Lot # A906423, exp. date Nov 2021.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0247-2021
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0247-2021. Report a data issue: hello@regdatalab.com.